Aclaris Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACRS Nasdaq 2834 www.aclaristx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclaris Therapeutics, Inc.

Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b - Oct 27th, 2026 4:04 pm
Aclaris Therapeutics Reports Positive Phase 1b ATI-052 Trial Results, Prices $50 Million Offering - Oct 27th, 2026 8:38 am
Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%? - Oct 27th, 2026 6:40 am
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants - Oct 27th, 2026 4:43 am
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma - Oct 27th, 2026 4:00 am
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? - Oct 21st, 2026 6:40 am
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock? - Sep 15th, 2026 6:47 am
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Sep 3rd, 2026 6:00 am
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Aug 10th, 2026 7:55 am
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - Aug 6th, 2026 2:35 pm
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates - Aug 6th, 2026 6:20 am
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Aug 6th, 2026 4:59 am
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Jul 1st, 2026 6:23 am
3 Penny Stocks Under $5 Backed by Real Revenue Growth - Jun 20th, 2026 7:20 am
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On - Jun 7th, 2026 11:59 am
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 - Jun 4th, 2026 1:02 pm
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - May 28th, 2026 6:30 am
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - May 8th, 2026 6:30 am
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates - May 7th, 2026 6:50 am